Platinum chemotherapeutics: A sonoactivated platinum anticancer prodrug ScienceAdvances naturechemistry
In vivo anticancer activity
The researchers next established a synergetic model based on the 4T1 murine mammary carcinoma cell line to resemble stage IV breast cancer in an. A 12-hour post-injection window provided an optimal therapeutic timeframe for sonoactivation. The scientists treated the tumors with focused ultrasound via programmable scanning to move the focus of ultrasonication to cover the entire region of interest.
Exploration of cancer cell death mode. Bright-field images of HeLa cells under various treatments. Vehicle control , cyaninplatin + focused ultrasound , celastrol , and carboplatin + ligand 1 + FUS. 5. Carboplatin + FUS, 6. ligand 1 + carboplatin, 7. ligand 1 + carboplatin + FUS. Confocal laser scanning microscopy images of cells with cytoplasmic vacuolation and depolarization of mitochondria. Western blot and quantitative results of HeLa cells with different treatment conditions.
The researchers also monitored tumor accumulation of cyaninplatin and the tissue penetration ability of focused ultrasound both in vivo and ex vivo. They confirmed the activation of cyaninplatin through ultrasound and confirmed the detection of reactive oxygen species by usingIn this way, Gongyuan Liu and colleagues developed cyaninplatin, a platinum prodrug activated and regulated by ultrasound.
In its mechanism of action, the sono-activated cyaninplatin generated reactive oxygen species and depleted intracellular reductants to mediate mitochondrial damage and cancer cell killing efficiency. This study further expands existing understanding of the sonoactivation process of small molecules to broaden the scope of biomedical ultrasound and sono-activatable prodrugs as additional therapeutic options for cancer medicine.